See more : SSE PLC (SCT.DE) Income Statement Analysis – Financial Results
Complete financial analysis of PhaseBio Pharmaceuticals, Inc. (PHAS) income statement, including revenue, profit margins, EPS and key performance metrics. Get detailed insights into the financial performance of PhaseBio Pharmaceuticals, Inc., a leading company in the Biotechnology industry within the Healthcare sector.
- Braille Energy Systems Inc. (BES.V) Income Statement Analysis – Financial Results
- Xalles Holdings Inc. (XALL) Income Statement Analysis – Financial Results
- Clean Motion AB (publ) (CLEMO.ST) Income Statement Analysis – Financial Results
- Valor Latitude Acquisition Corp. (VLATU) Income Statement Analysis – Financial Results
- Retail Value Inc. (RVIC) Income Statement Analysis – Financial Results
PhaseBio Pharmaceuticals, Inc. (PHAS)
About PhaseBio Pharmaceuticals, Inc.
PhaseBio Pharmaceuticals, Inc., a clinical-stage biopharmaceutical company, focuses on the development and commercialization of novel for cardiovascular diseases. Its lead product candidate is bentracimab (PB2452), a reversal agent for the antiplatelet drug ticagrelor that is in Phase III clinical trial for patients with uncontrolled major or life-threatening bleeding events or in patients requiring urgent or an invasive procedure. The company is also developing PB1046, a vasoactive intestinal peptide analogue for the treatment of pulmonary arterial hypertension; and PB6440 for the treatment of resistant hypertension. The company has a co-development agreement with SFJ Pharmaceuticals X, Ltd. to develop PB2452, a reversal agent for the antiplatelet drug ticagrelor. PhaseBio Pharmaceuticals, Inc. was incorporated in 2002 and is based in Malvern, Pennsylvania. On October 23, 2022, PhaseBio Pharmaceuticals, Inc. filed a voluntary petition for reorganization under Chapter 11 in the U.S. Bankruptcy Court for the District of Delaware.
| Metric | 2021 | 2020 | 2019 | 2018 | 2017 | 2016 |
|---|---|---|---|---|---|---|
| Revenue | 10.83K | 320.00K | 2.36M | 668.00K | 0.00 | 0.00 |
| Cost of Revenue | 0.00 | 319.68K | 0.00 | 0.00 | 0.00 | 0.00 |
| Gross Profit | 10.83K | 320.00 | 2.36M | 668.00K | 0.00 | 0.00 |
| Gross Profit Ratio | 100.00% | 0.10% | 100.00% | 100.00% | 0.00% | 0.00% |
| Research & Development | 102.11K | 72.09M | 30.91M | 15.46M | 6.21M | 7.38M |
| General & Administrative | 16.09K | 13.09M | 11.19M | 4.86M | 2.33M | 2.13M |
| Selling & Marketing | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 |
| SG&A | 16.09K | 13.09M | 11.19M | 4.86M | 2.33M | 2.13M |
| Other Expenses | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 |
| Operating Expenses | 118.19K | 85.18M | 42.10M | 20.31M | 8.54M | 9.50M |
| Cost & Expenses | 118.19K | 85.18M | 42.10M | 20.31M | 8.54M | 9.50M |
| Interest Income | 14.00 | 237.00K | 1.58M | 387.00K | 52.00K | 29.00K |
| Interest Expense | -947.00 | 1.45M | 1.08M | 3.92M | 2.72M | 0.00 |
| Depreciation & Amortization | 1.79M | 508.00K | 174.00K | 105.00K | 96.00K | 92.00K |
| EBITDA | 1.66M | -96.61M | -38.00M | -19.82M | -7.43M | -9.13M |
| EBITDA Ratio | 15,350.22% | -30,191.25% | -1,609.36% | -2,966.62% | 0.00% | 0.00% |
| Operating Income | -130.42K | -84.86M | -39.74M | -19.64M | -8.54M | -9.50M |
| Operating Income Ratio | -1,204.12% | -26,517.50% | -1,683.02% | -2,940.72% | 0.00% | 0.00% |
| Total Other Income/Expenses | 947.00 | -13.71M | 489.00K | -4.20M | -1.71M | 281.00K |
| Income Before Tax | -129.47K | -98.57M | -39.25M | -23.85M | -10.25M | -9.22M |
| Income Before Tax Ratio | -1,195.37% | -30,801.56% | -1,662.30% | -3,569.76% | 0.00% | 0.00% |
| Income Tax Expense | 1.60K | -12.26M | 1.57M | -278.00K | 1.01M | 281.00K |
| Net Income | -131.07K | -98.57M | -39.25M | -23.85M | -10.25M | -9.22M |
| Net Income Ratio | -1,210.15% | -30,801.56% | -1,662.30% | -3,569.76% | 0.00% | 0.00% |
| EPS | 0.00 | -3.39 | -1.43 | -4.49 | -0.91 | -0.74 |
| EPS Diluted | 0.00 | -3.39 | -1.43 | -4.49 | -0.91 | -0.74 |
| Weighted Avg Shares Out | 29.40M | 29.06M | 27.49M | 5.31M | 11.25M | 12.39M |
| Weighted Avg Shares Out (Dil) | 29.40M | 29.06M | 27.49M | 5.31M | 11.25M | 12.39M |
PhaseBio Plans for Near-Term Sale Using Structured Process Through Chapter 11 of U.S. Bankruptcy Code
These Were The Five Best And Worst Performing Healthcare Stocks In September 2022
PhaseBio Pharmaceuticals (PHAS) Reports Q2 Loss, Lags Revenue Estimates
PhaseBio Pharmaceuticals Reports Second Quarter 2022 Financial Results and Recent Business Highlights
PhaseBio Pharmaceuticals Reports Second Quarter 2022 Financial Results and Recent Business Highlights
PhaseBio Pharmaceuticals (PHAS) Reports Q1 Loss, Misses Revenue Estimates
PhaseBio Pharmaceuticals Reports First Quarter 2022 Financial Results and Recent Business Highlights
PhaseBio Pharmaceuticals Reports First Quarter 2022 Financial Results and Recent Business Highlights
PhaseBio Announces Successful Pre-BLA Meeting with U.S. FDA for Bentracimab
Source: https://incomestatements.info
Category: Stock Reports